Company Update

E.I.D. – Parry: Sells Entire Stake in Algavista Greentech

E.I.D.-Parry (India) Limited has approved the sale of its entire 50% stake in the Joint Venture Company, Algavista Greentech Private Limited. The decision was...

E.I.D.- Parry: De-classification of Certain Persons from Promoter Group

E.I.D.- Parry (India) Limited announced the de-classification of certain persons from the ‘Promoter and Promoter Group’ category. The company's Board of Directors approved the...

Multi Commodity Exchange: GST Department Issues Show Cause Notice

The Multi Commodity Exchange of India (MCX) has received a show cause notice from the GST Department on September 18, 2025. The notice pertains...

Kaynes Technology: CEO Rajesh Sharma Announces Resignation

Kaynes Technology has announced the resignation of its Chief Executive Officer, Rajesh Sharma, effective from the close of business hours on October 31, 2025....

Asahi India Glass: Allotment of Equity Shares via Qualified Institutions Placement

Asahi India Glass Limited successfully completed its Qualified Institutions Placement (QIP) of ₹1,000 Crore. The LTP Committee approved the allotment of 1,18,37,261 Equity Shares...

CESC: Green Power Arm to Establish 3+ GW Solar Cell Plant

CESC's wholly-owned subsidiary, CESC Green Power Ltd, is set to establish a 3+ GW solar cell/module plant along with battery manufacturing and a 60...

BLS International: Outcome of Annual General Meeting Held on September 16, 2025

BLS International has announced the key outcomes of its Annual General Meeting (AGM) held on September 16, 2025. The shareholders approved the appointment of...

Glenmark: Outlook Revised to Positive Following AbbVie Licensing Deal

Glenmark Pharmaceuticals' outlook has been revised to Positive by Crisil Ratings, following its exclusive licensing deal with AbbVie for ISB 2001. The deal includes...

Aurobindo Pharma: CuraTeQ Announces Positive Phase 3 Results for Denosumab Biosimilar

CuraTeQ Biologics, a subsidiary of Aurobindo Pharma, announced the successful completion of a Phase 3 clinical study for its denosumab biosimilar. The study, involving...

Latest articles